Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P26640

UPID:
SYVC_HUMAN

ALTERNATIVE NAMES:
Protein G7a; Valyl-tRNA synthetase

ALTERNATIVE UPACC:
P26640; B0V1N1; B4DZ61; Q5JQ90; Q96E77; Q9UQM2

BACKGROUND:
Protein G7a, or Valyl-tRNA synthetase, is pivotal in the protein synthesis process, ensuring the proper addition of valine to tRNA(Val). Its function is fundamental in translating genetic codes into proteins, crucial for cellular function and health.

THERAPEUTIC SIGNIFICANCE:
Linked to a severe neurodevelopmental disorder, the study of Valine--tRNA ligase offers a promising avenue for developing targeted treatments. Exploring its function and involvement in disease mechanisms could lead to breakthrough therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.